378 - Response to neoadjuvant therapy and disease free survival and overall survival in patients with triple-negative breast cancer (TNBC): single center...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer
Presenter Tomas Pascual
Authors T. Pascual1, E. Ciruelos2, L. Manso2, I. Ghanem2, R.A. Manneh2, C. Mendiola2, D. Lora3, H. Cortes-Funes1
  • 1Servicio De Oncologia Medica, Hopital 12 de Octubre, 28005 - Madrid/ES
  • 2Medical Oncology, Hopital 12 de Octubre, 28005 - Madrid/ES
  • 3Clinical Investigation Unit, Imas12, University Hospital 12 de Octubre, Madrid/ES



Triple negative breast cancer (TNBC) is a distinct subtype of BC wich is characterized by the absence of expression of estrogen receptor (ER), progesterone receptor (PR) or HER2/neu. TNBC is a very heterogeneous disease, that accounts for 15 to 20% of breast cancers. Despite initial chemosensitivity, patients with TNBC had a poorer outcome in terms of disease-free and overall survival, compared to non-triple-negative breast cancers. Neoadjuvant chemotherapy is commonly used for the initial treatment for TNBC, allowing for a higher rate of breast-conserving surgery and giving clues about the individual responsiveness of a particular cancer to chemotherapy.


We retrospectively reviewed 66 TNBC patients treated with neoadjuvant chemotherapy diagnosed at our institution between 2001-2011. They were divided into three subgroups: complete pathological response after neoadjuvant chemotherapy (group A), residual tumor smaller than 1 centimeter wide (group B), and residual tumor bigger than 1 centimeter wide or involving lymph nodes.


(One patient died before surgery and another patient refused it. Twenty (31%) of the other 64 patients achieved a complete pathological response. Mean DFS was 2,15 years; recurrent disease was higher for C (20,64%) vs B (3pts, 23%) vs A (2 pts, 10%) (p = 0,0003). Most common recurrent sites were local (18) and bone (9). Mean OS was 4,5 years (95% IC 3,6 – 5,4); 3 (15%) pts died in A, 3 (23%) in B vs 16 (51%) in C (p = 0,03).


The pathologic complete response rate seen in our series is consistent with the one reported in other studies involving neoadjuvant chemotherapy for TNBC. The pathologic response after a neoadjuvant therapy correlates with disease-free and overall survival rates.


All authors have declared no conflicts of interest.